Council of Scientific and Industrial Research

Other

Colgate Palmolive Company

Zandu Pharmaceutical Works Ltd.

Indian Institute of Integrative Medicine

Krishan Avtar Suri

Naresh Kumar Satti

Om Parkash Suri

Ghulam Nabi Qazi

Bal Krishan Chandan

Kasturi Lal Bedi

Vikram Bhardwaj

Bishan Datt Gupta

Sukhdev Swami Handa

Vishwa Nath Gupta

Rakesh Kamal Johri

Anamika Khajuria

Bupinder Singh Jaggi

Bal Krishan Kapahi

Subhash Chander Sharma

Ashok Kumar Tikoo

Manoj Kumar Tikoo

Inshad Ali Khan

Anpurna Kaul

Om Prakash Suri

Ravi Kant Khajuria

Prabhakar Kulhar

Raman Krishnamurthy

Ulhas Salunkhe

Girish G Parikh

Neelam Sharma

Surjit Singh

Bupinder Singh

Ravi Subramanyam

Laurence Du-Thumm

Furqan Ali

Rakesh Tuli

Ajit Kumar Saxena

Rakesh Maurya

Vijeshwar Verma

Rajender Singh Sangwan

Ashwani Kumar

Nitin Pal Kalia

Neelam Singh Sangwan

Gulam Nabi Qazi

Girish Chandra Uniyal

Lila Ram Manhas

Avdhesh Kumar Srivastava

Sheikh Tasaduq Abdullah

Gurdarshan Singh

Anil Prabhakar

Vijay Kumar Sharma

Jyotsna Suri

Madalsa Bargotra

Swadesh Malhotra

Kuldip Kumar Gupta

Payare Lal

Shankar Lal

Bhupinder Singh

V N Gupta

Narayan Das Chaurasiya

Musarat Amina

Sheikh Tasaduq Absullah

Laxmi Narayan Misra

Compounds are described that are effective in enhancing the efficacy of antimicrobial agents. Also described are methods of using such compounds and compositions that include such compounds. The composition includes a chalcone compound and, optionally, an antimicrobial agent.

Chalcones as enhancer of antimicrobial agents

The present invention relates to a synergistic formulation comprising trans-tetracos-15-enoic acid (t-TCA) and andrographolide (AP) in the ratio ranging between 1:7 to 7:1 (w/w), useful in hepatoprotection; and a process for the preparation of a synergistic formulation comprising trans-tetracos-15-enoic acid (t-TCA) and andrographolide (AP) useful in hepatoprotection, said process comprising steps of grounding the particles of the t-TCA and AP into fine particles, mixing the fine particles in ratio ranging between 1:7 to 7:1 (w/w), and grinding the mixture to obtain formulation, and also, a method of hepatoprotection of a subject using the synergistic formulation comprising trans-tetracos-15-enoic acid (t-TCA) and andrographolide (AP), said method comprising the steps of administering the formulation to the subject.

Synergistic hepatoprotective composition and a method thereof

The present invention relates to a bioenhancing/bioavailability-facilitating composition comprising:

[object Object]

The present invention provides a method for treating and/or preventing hepatic disease conditions in a subject mammals including human beings, said method comprising the steps of administering to the mammal an effective dosage of composition comprising 2'-p-Hydroxy benzoyl mussaenosidic acid from plantoptionally as individual or in combination with one or more pharmaceutically additives.

Hepatoprotective activity of 2'-p-hydroxybenzoylmussaenosidic acid

The present invention relates to a pharmaceutical composition comprising a bioactive constituent trans-tetracos-15-enoic acid and a process for the isolation of tetracos-15-enoic acid from the plantalong with a method of treatment for hepatotoxicity.

Pharmaceutical composition and process for isolation of trans-tetracos-15-enoic acid and method of treatment for hepatotoxicity

The present invention relates to the use of bioenhancers to decrease the resistance of microbial strains to anti-infective such an antibiotics and antifungals by potentiating the activities of anti-infective. This may be useful to reduce resistance in bacteria and yeast to aid in the treatment of certain infections and disease and to lower the concentration of antiinfectives necessary to inhibit the growth of microbial strains.

Use of herbal agents for potentiation of bioefficacy of anti infectives

The present invention relates to an improved process of analytical and quantitative isolation of withaferin-A from(Sanskrit: Ashwagandha, English: winter cherry) and other plants and products therefrom, said method comprising steps of selecting most appropriate extraction medium composition, with extraction solvent system consisting of a defined admixture of water and alcohol in a range of proportion of alcohol within a narrow range of (methanol, ethanol etc.) (preferably 60% alcohol and 40% water) for the dry plant material and from 60% to 80% alcohol in the alcohol-water mixture for fresh plant material, the invented extractant composition leading to better/improved yields and accurate quantitative estimations of withaferin A existent in planta or in materia, selecting effective state of the tissue particularly use of the fresh materials improving yields, providing logistic benefits of isolations and diagnosis, and according several other advantages including technological, economic, preventing contaminations etc., the said method being valuable and advantageous for standardization of botanicals, metabolomic characterization of plants particularly chemotypes, analyzing metabolic transitions under physiological, genetical, environmental and biotic perturbations.

Process for isolation of withaferin-A from plant materials and products therefrom

A process of isolation of pure Acteoside of high hepatoprotection from plant, said process comprising steps of drying aerial parts of the plant, grounding the dried parts into powder, percolating the powder with water or ethanol for 3-4 times to obtain an extract, filtering the extract for clearing of suspended particles to obtain supernatant, drying the supernatant at about 45 to 55&#xb0; C. to obtain a residue, fractionating the residue with chloroform, ethyl acetate, and butanol successively, subjecting butanol fraction to adsorption chromatography of SiOafter adding methanol to the fraction, charging the adsorbed fraction to glass column, eluting the column with solvents of increasing polarity of methanol:chloroform to obtain further fractions and repeating the process one more time, subjecting the fractions to column chromatography to obtain fractions, concentrating the fractions under reduced pressure to obtain acteoside as residue; and a method of effectively hepatoprotecting a subject using pure Acteoside from plant, said method comprising steps of administering appropriate low-dose of the acteoside to the subject.

Hepatoprotective agent of plant origin and a process thereof

The present invention relates to a synergistic hepatoprotective pharmaceutical composition comprising an effective amount of trans-tetracos-15-enoic acid (TCA) and Apocynin (APO), the present invention also relates to a method of treatment for hepatotoxicity in mammals and humans.

Synergistic composition of trans-tetracos-15-enoic acid and Apocynin and method of treatment for hepatotoxicity

The present invention relates to a composition useful for hepatoprotection, said composition comprising polar extract of plantand/or fractions of the said extract, and optionally pharmaceutically acceptable additives and a method of producing said composition and also a method of treating a subject using said composition.

Composition useful as hepatoprotectants comprising extract of plant Cryptolepis buchanani and a method thereof

The present invention relates to a process for the preparation of trans-alkenoic acids of general formula CH&#x2014;(CH)n&#x2014;CH&#x2550;(CH)mCOH where n=4 to 9 m=8 to 16. More particularly, the present invention relates to a process for the preparation of trans-tetracos-15-enoic acid, which is a bioactive constituent possessing dose-related hepatoprotective activity. The present invention also relates to the use thereof for hepatoprotection.

Process for the synthesis of trans-alkenoic acids, use thereof

The present invention relates to a process for the isolation of a novel oligospirostanoside structurally constructed as 3-0-&lsqb;&agr;-L-rhamnopyranosyl-(1&rarr;2)-&agr;-L-rhamnopyranosyl-(1&rarr;4)-0-&bgr;-D-glucopyranosyl&rsqb;-25(S)-5&bgr; spirostan-3&bgr;-ol isolated from and biologically evaluated as a potent immunomodulatory agent.

Process for the isolation of novel oligospirostanoside

The present invention relates to a novel oligospirostanoside having the structure 3-0-&lsqb;&agr;-L-rhamnopyranosyl-(1&rarr;2)-&agr;-L-rhamnopyranosyl-(1&rarr;4)-0-&bgr;-D-glucopyranosyl&rsqb;-25(S)-5&bgr;-spirostan-3&bgr;-ol isolated from and to a pharmaceutical composition containing the novel oligospirostanoside and to a method for immunomodulation using said oligospirostanoside by administering a pharmaceutically effective amount of said novel oligospirostanoside.

Oligospirostanoside, pharmaceutical composition containing novel oligospirostanoside and method for immunomodulation using said oligospirostanoside

Growing community of inventors

Jammu, India

Krishan Avtar Suri